SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly earnings report and ambitious AI-compute expansion outlook are fueling bullish interest, while traders debate the spending plans, valuation, and potential Tesla merger. The large share unlock and profit-taking are tempering enthusiasm, with some traders viewing the added supply as a risk to the post-earnings rally.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

The distribution and separate trading of long-dated warrants has driven sharp price swings and confusion over whether the share-price drop was mainly a mechanical adjustment or a loss in value. Some holders say the shares and warrants should be considered together, while skeptics point to dilution and the heavy debt from the Warner Bros. Discovery deal.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives expanded Bitcoin treasury and the closing/listing of its SATS preferred offering are fueling attention, with bulls viewing the proceeds as capital for further Bitcoin purchases. The rally is drawing enthusiasm, while skeptics warn that the high dividend burden and potential share issuance could weigh on common shareholders.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its earnings report, with traders debating whether the recent selloff reflects pre-report profit-taking or a possible leak; claims of leaked results remain speculation. Some see the pullback as a buying opportunity, while others are wary of further downside and the options-implied move.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the dominant focus, with traders watching AI spending guidance and whether the Muse rollout can show traction and justify the investment. Views are split: bulls expect AI momentum to support growth, while bears worry that rising capex, weaker cash flow and a New Mexico privacy ruling could weigh on the stock.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags is under pressure after Mizuho cut its outlook, amid continued fallout from a fatal roller-coaster accident, precautionary ride closures, and fresh safety concerns. Bears worry about reputational damage, legal exposure, and the companys debt, while some traders view the selloff as overdone and point to short-squeeze potential.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD is drawing attention after its latest earnings report showed a revenue decline but improved profitability and cash flow, yet shares sold off sharply. Traders are debating whether the drop is an overreaction to otherwise solid results or reflects weak Chinese consumer demand and persistent pressure on the companys growth.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention amid a steep selloff and concerns about potential hedging losses, debt maturities, and whether its distribution is sustainable ahead of earnings. Holders are frustrated by Icahns limited communication, while some bullish traders point to IEPs CVR Energy stake and speculate about a short squeeze or a rebound.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly earnings miss and sharply lower fourth-quarter profit guidance, driven by elevated fuel costs, are prompting debate as shares rally despite the weak outlook. Traders are weighing margin pressure against record revenue, resilient travel demand and expectations for continued revenue growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of an FDA decision on deramiocel for Duchenne muscular dystrophy, particularly the narrowed application focused on upper-limb function and the HOPE-3 data. Traders are divided: some see a path to approval, while others cite the prior advisory committee vote and disputed statistical analyses as risks; the uncertainty is fueling volatile trading and speculation about short-selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
CalciMedica (NASDAQ:CALC) shares roseread more...

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

Equity

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 


These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...

Why Is Pharvaris Stock Soaring Tuesday?

Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.read more...

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharvaris (PHVS) Expected to Announce Earnings on Tuesday

Pharvaris (NASDAQ:PHVS) will be releasing earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-pharvaris-nv-stock...

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Pharvaris NV

Bullish Sentiment

<ul class="summary-bullets"><li>BioCryst’s Orladeyo is approved to prevent HAE attacks.&nbsp;</li><li>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year.</li><li>BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success.</li></ul><p>Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst’s main product.</p><p>BCRX fell 9% on Tuesday and clocked its worst day since late February. &nbsp;</p><h2 class="st-heading-2">A Rival Pill Raises The Bar</h2><p>The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours.</p><p>That market is the same one served by BioCryst’s Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027.</p><h2 class="st-heading-2">Orladeyo Market</h2><p>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027.</p><p>BioCryst CEO Charlie Gayer <a href="https://stocktwits.com/news-articles/markets/equity/bio-crysts-orladeyo-built-the-cash-pile-ceo-gayer-wants-to-buy-the-next-asset/cZYAopbRJrb">said</a> last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind.</p><h2 class="st-heading-2">How Did BCRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around BCRX rose from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. “I’m really not worried.. it will go up sooner than later.. market trying to get rid of the weak hands,” they said.</p><p><stembedurl>https://stocktwits.com/Ray52baltimore/message/663832998</stembedurl></p><p>Another user opined that no one will switch out of Orladeyo even if Pharvaris’s drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products.</p><p><stembedurl>https://stocktwits.com/SCCT2FL/message/663813354</stembedurl></p><p><a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> has gained 16% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-drops-jefferies-sees-possible-snag-to-in-cabin-experience-owing-to-spcx-vsat-spectrum-fight/cZtE95BRJy5">DAL Stock Drops: Jefferies Sees Possible Snag To In-Cabin Experience Owing To SPCX-VSAT Spectrum Fight</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 

Biocryst Pharmaceuticals Inc.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$30.90
Prev Close	$30.90
Open	$30.81
Dividend Yield	0.00%
50-Day Moving Average	$34.22
Beta	0.75
Avg. Volume	1.09M
PE Ratio	-10.13

52-Week High	$43.25
52-Week Low	$21.02
Market Capitalization	$2.16B
EPS (Annual)	-$3.35
Price to Book	6.31
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHVS Fundamentals